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Abstract
For designing, monitoring and analyzing a longitudinal study with an event time as
the outcome variable, the restricted mean event time (RMET) is an easily interpretable,
clinically meaningful summary of the survival function in the presence of censoring.
The RMET is the average of all potential event times measured up to a time point ;
which can be estimated consistently by the area under the Kaplan-Meier curve over
[0;  ]: In this paper, we present inference procedures for model-free parameters based
on RMETs under the one- and two-sample settings. We then propose a new regression
model, which relates the RMET to its covariates directly for predicting the subject-
specic RMETs. Since the standard Cox and the accelerated failure time models can
also be used for estimating such RMETs, we utilize a cross validation procedure to
select the \best" working model. Lastly we draw inferences for the subject-specic
RMETs based on the nal candidate model using an independent data set or a \hold-
out" sample from the original data set. All the proposals are illustrated with the data
from the a HIV clinical trial conducted by the AIDS Clinical Trials Group and the
PBC study conducted by the Mayo Clinic.
Keywords: Accelerated failure time model; Cox model; cross validation, hold-out
sample, personalized medicine; perturbation-resampling method
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1 Introduction
For a longitudinal study with time T to a specic event as the primary outcome variable,
commonly used summary measures for the distribution of T are the mean, median or t-year
event rate. Due to potential censoring for T , the mean may not be well estimated. If the
censoring is heavy, the median cannot be identied empirically either. The t year survival
rate may not be suitable for summarizing the global prole of T . On the other hand, based
on the design of the study and clinical considerations, one may pre-specify a time point 
and utilize the expected value  of Y = min(T; ), the so-called restricted mean event time
(RMET), as a summary parameter. This parameter is the mean of T for all potential study
patients followed up to time  , which has a heuristic and clinically meaningful interpretation
(Irwin, 1949; Karrison, 1987; Zucker, 1998; Murray & Tsiatis, 1999; Chen & Tsiatis, 2001;
Andersen et al., 2004; Zhang & Schaubel, 2011; Royston & Parmar, 2011; Zhao et al., 2012).
Moreover, this model-free parameter can be estimated consistently via the standard Kaplan-
Meier (KM) curve, that is, the area under the curve up to : Inferences about the RMET
can be obtained accordingly.
For a study for comparing two groups, say, A and B; with event time observations,
practitioners routinely use the hazard ratio to quantify the between-group dierence. When
the proportional hazards assumption is not valid, the standard maximum partial likelihood
estimator of the hazard ratio approximates a parameter which is dicult, if not impossible,
to interpret as the treatment contrast (Kalbeisch & Prentice, 1981; Lin & Wei, 1989; Xu
& O'Quigley, 2000; Rudser et al., 2012). Moreover, this parameter depends, oddly, on the
nuisance, study-specic censoring distributions. It follows that the hazard ratio estimators
at the interim and nal analyses from the same study or estimators from independent studies
with an identical study population would estimate dierent, uninterpretable parameters due
to dierential follow-up patterns. In fact, any model-based estimate in survival analysis may
have this problem. Therefore, it is highly desirable to consider an estimable, model-free
and censoring-independent parameter to quantify the treatment dierence for coherent and
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consistent assessments between interim and nal analyses within a study, as well as across
independent studies. Model-free parameters for the treatment dierence can be constructed
via two RMETs, say, A and B. As an example, to evaluate the added value of a potent
protease inhibitor, indinavir, for HIV patients, a pivotal study ACTG 320 was conducted
by the AIDS Clinical Trials Group (ACTG). This randomized, double-blind study (Hammer
et al., 1997) compared a three-drug combination, indinavir, zidovudine and lamivudine, with
the standard two-drug combination, zidovudine and lamivudine. There were 1156 patients
enrolled for the study. One of the endpoints was the time to AIDS or death with the follow-
up time about one year for each patient. Figure 1 presents the Kaplan-Meier curves for
these two treatment groups. The hazard ratio estimate is 0.50 and the corresponding 0.95
condence interval is (0.33, 0.76) with a p-value of 0.001. It is not clear if the proportional
hazard assumption is valid for this study. With  = 300 days, the estimated RMET (the area
under the KM curve up to 300 days) was 277 days for the control and was 288 days for the
three-drug combination. The estimated dierence with respect to the RMET is 11 days with
the corresponding 0.95 condence interval of (3.2, 17.3) and a p-value of 0.005. Although
the treatment ecacy for the three drug combination is highly statistically signicant, its
clinical benet is debatable, considering the relatively short follow-up time of the study. On
the other hand, if we mimic the concept of the hazard ratio or relative risk as a summary
measure for the treatment contrast, one may consider a model-free ratio R of (   B) and
(  A): With the above HIV data, if B is the new treatment with three drug combination,
the estimated R is 0.55 with a p-value of 9:310 6; also an impressive statistically signicant
result. For a single arm, (   ) is the average of the days lost from the healthy state up to
; a meaningful alternative to  as a summary parameter for the distribution of T: Note that
the above condence interval estimates and p-values were obtained using a perturbation-
resampling method detailed in Section 2.
In this paper, we rst present the inference procedures for one- and two-sample problems
and then consider regression models for the RMET. For the regression analysis, our goal
3
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is to build a prediction model via an extensive model selection process to stratify future
patients using the patients' \baseline" covariates. The existing regression models such as
the Cox model can be candidates to create such a stratication system. However, it seems
more natural to model the RMET with the covariates directly, not via the hazard function
(Andersen et al., 2004). In this article, we consider a new class of models which takes
this approach and study the properties of the corresponding inference procedures. Since
it is unlikely that any model will be precisely correct, our ultimate goal is to choose the
best \tted" model to stratify the future patients. To avoid overly optimistic results, we
randomly split the data set into two pieces. Based on the rst piece, called the training
set, we utilize a cross validation procedure to build and select the nal model. We then use
the second data set, called the holdout set, to make inferences about the RMETs over a
range of scores created from the nal model. We use a data set from a well-known clinical
study conducted at Mayo Clinic (Therneau & Grambsch, 2000) for treating a liver disease
to illustrate the proposals for individualized prediction.
2 One- and two-sample inference procedures for RMET
For a typical subject with event time T , let Z be the corresponding q-dimensional baseline
covariate vector. Suppose that T is subject to right censoring by a random variable C,
which is assumed to be independent of T and Z. The observable quantities are (U;; Z),
where U = min(T;C),  = I(T  C), and I() is the indicator function. The data,
f(Ui;i; Zi); i = 1; : : : ; ng, consist of n independent copies of (U;; Z). Suppose that for
a time point ; pr(U  ) > 0: The restricted survival time Y = min(T; ) may also be
censored, but its expected value  is estimable. Let Yi be the corresponding Y for the ith
subject, i = 1; : : : ; n: A natural estimator for  is
^ =
Z 
0
S^(u)du;
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where S^(u) is the KM estimator for the survival function of T based on f(Ui;i); i =
1; : : : ; ng: Alternatively, one may employ the inverse probability censoring weighting method
to estimate  as
~ = n 1
nX
i=1
~i
G^(Yi)
Yi;
where ~i = I(Yi  Ci) and G^() is the KM estimator of the censoring time C based on
f(Ui; 1 i); i = 1; : : : ; ng: In Appendix A we show that ~ and ^ are asymptotically equiva-
lent at the root n rate. Similar observations had been made by Satten & Datta (2001) with
respect to KM estimator and its inverse weighting counterpart. It is straightforward to show
that as n!1, n1=2(^ ) is approximately normal with mean zero and variance 2; which
can be estimated analytically or by a perturbation-resampling method. Specically, let
 = n 1
nX
i=1
~i
G(Yi)
YiQi;
where fQ1;    ; Qng are positive random variables with unit mean and variance and inde-
pendent of the observed data and G() is a perturbed version of the KM estimator of the
censoring variable. Here,
G(t) = G^(t)
 
1  1
n
nX
i=1
Z t
0
dM^Ci (u)Pn
j=1 I(Uj  u)
Qi
!
;
M^Ci (u) = I(Ui  u)(1 i) 
R u
0
I(Ui  s)d^C(s) and ^C(v) is the Nelson-Aalen estimator for
the cumulative hazard function of the censoring time C: Then given the data, the conditional
distribution of n1=2( ^) converges to the unconditional limiting distribution of n1=2(^ ):
In practice, one may generate a large number, say, M; of replications of fQ1;    ; Qng and
calculate the corresponding : Then the empirical distribution of M generated s can
be used to make inference about : This resampling technique has been used for various
applications in survival analysis and in general preforms better than its analytical counterpart
(Tian et al., 2005; Uno et al., 2007; Li et al., 2011). Moreover, if we are interested in a function
5
Hosted by The Berkeley Electronic Press
of ; say, g1(); one can utilize M realizations of g1(
) for making inference. Note that for
censored data, the standard bootstrapping method may generate a KM curve which is not
dened at time  and  would not be estimable via this bootstrap sample.
For the two-sample problem, let Z be A or B as in the Introduction. Let the correspond-
ing means  be denoted by A and B and their estimators by ^A and ^B; respectively.
Suppose we are interested in estimating a model-free parameter  = g2(A; B); where
g2(; ) is a smooth bivariate function. For example, g2(a; b) = b  a; b=a; (   a)=(   b) or
fb=(   b)g=fa=(   a)g: Then  can be estimated consistently with ^ = g2(^A; ^B) and its
variance estimate can be obtained via the delta-method. Alternatively, the distribution of
(^ ) can be approximated by the conditional distribution of ( ^); where  = g2(A; B)
and A and 

B are the perturbed 
 for groups A and B; respectively. The 0.95 condence
interval estimates and p-values for the HIV example in the Introduction were obtained with
M = 1000 and Qs generated from the unit exponential.
3 Regression Models for RMET
If the parameter of interest is the RMET, it is natural to model
(z) = E(Y jZ = z)
with the covariate vector Z = z directly (Andersen et al., 2004). For example, one may
consider
f(z)g = 0X; (1)
where () is a given smooth, strictly increasing function from [0;  ] to the real line,  is
a (q + 1)-dimension unknown vector and X 0 = (1; Z 0): A special link function is (a) =
logfa=(   a)g; which mimics the logistic regression. Note that with this specic link, for
6
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the two sample problem, the regression coecient of the treatment indicator is
log

B(   A)
A(   B)

;
an odds-ratio like summary for the group contrast, which was used for analyzing HIV data
discussed in the Introduction.
For the general link function (); following the least squares principle, an inverse prob-
ability censoring weighted estimating function of  is
Sn() = n
 1
nX
i=1
~i
G^(Yi)
Xi

Yi    1(0Xi)
	
:
Let ^ be the unique root of Sn() = 0: Under mild regularity conditions, one can show that
Sn() uniformly converges to a monotone limiting function
S() = E

X

(Z)   1(0X)	
in probability. Let  be the root of S() = 0: It follows that ^ converges to  in probability,
even when the model is misspecied. As n!1; n1=2(^  ) converges weakly to a mean zero
Gaussian distribution. Moreover, we can make statistical inference for  via the perturbation-
resampling methods similar to those given in the previous section. Specically, let  be the
root of the perturbed estimating equation
n 1
nX
i=1
~i
G^(Yi)
Xi

Yi    1(0Xi)
	
Qi = 0:
It follows from the argument similar to that in Lin et al. (1993), Park & Wei (2003), and
Tian et al. (2005) that the conditional distribution of n1=2(   ^) given the observed data
can approximate the unconditional limiting distribution of n1=2(^   ): In Appendix B, we
justify this large sample approximation.
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Note that Andersen et al. (2005) studied models such as (1) via a log-link () using
a psedo-observation technique to make inferences about the regression coecient assuming
the model is correctly specied. It can be shown that in general our estimator ^ would
converge to the same parameter as that with the procedure taken by Andersen et al. (2005)
when the model (1) is correctly specied. It would be theoretically interesting to compare the
eciency of these two procedures with respect to the estimation of the regression coecients.
However, since it is unlikely that the working model would be correctly specied, in practice
it seems more relevant to evaluate such a model from the prediction point of view as we do
in this article.
Using the above model, one may estimate (z) by ^(z) =  1(^0x), for any xed Z = z;
where x0 = (1; z0): The distribution of f^(z)   1( 0x)g can be approximated by the above
resampling method. Note that (z) can also be estimated via, for example, a Cox model
(Cox, 1972). Specically, let the hazard function for given z be
(tjZ = z) = 0(t)e0z;
where  is a q-dimensional unknown vector and 0() is the nuisance baseline hazard function.
It follows that (z) can be estimated by
^(z) =
Z 
0
expf ^0(s)e^0zgds;
where ^ and ^0(s) are the maximum partial likelihood estimator for  and the Breslow
estimator for 0(s) =
R s
0
0(v)dv; respectively.
Alternatively, one may use the accelerated failure time (AFT) model (Kalbeisch &
Prentice, 2002)
log(T ) = 0Z + ;
to make inference about (z), where  is a q-dimensional unknown vector and  is the error
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term whose distribution is entirely unspecied. Here,  can be estimated via a rank-based
estimating function (Ritov, 1990; Tsiatis, 1990; Wei et al., 1990; Jin et al., 2003). Let ^
be the corresponding estimator for : One may estimate the survival function of e by KM
estimator based on the data f(Uie ^0Zi ;i); i = 1;    ; ng: Let the resulting estimator be
denoted by S^0(): Then one can estimate (z) by ^(z) =
R 
0
S^0(e
 ^0zs)ds: Note that when
pr(C > e
0Z sup e) > 0; ^(z) is estimable for any given covariate z: In practice, we can always
set the censoring indicator at one for the observation with the largest Uie
 ^0Zi in estimating
the survival function of e: Although these estimators for (z) may not be consistent and
in general depend on the censoring distribution under misspecied model, they still can be
reasonable predictions for the RMET.
4 Model Selection and Evaluation
All the models for estimating (z) discussed in the previous section are approximations to
the true model. To compare these models, one may compare the observed restricted event
time Y with the covariate vector z and its predicted ^(z): A reasonable predicted error
measure is EjY   ^(Z)j; where the expected value is with respect to the data and the future
subject's (Y; Z): If there is no censoring, the empirical apparent prediction error is
n 1
nX
i=1
jYi   ^(Zi)j;
which is obtained by rst using the entire data to compute ^() and then using the same
data to estimate the predicted error. Such an estimator may be biased downward (Stone,
1974; Geisser, 1975). An alternative is to utilize a cross-validation procedure to estimate
such a predicted error (Tian et al., 2007; Uno et al., 2007).
Specically, consider a class of models for (Z): For each model, we randomly split the
data set into K disjoint subsets of approximately equal sizes, denoted by fIk; k = 1; : : : ; Kg.
For each k, we use all observations which are not in Ik to obtain a model-based prediction
9
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rule ^( k)(Z) for Y , and then estimate the total absolute prediction error for observations
in Ik by
D^k =
X
j2Ik
~j
G^(Yj)
Yj   ^( k)(Zj) :
Then we use the average n 1
PK
k=1 D^k as a K-fold cross-validation estimate for the absolute
prediction error. We may repeat the aforementioned procedure a large number of, say B;
times with dierent random partitions. Then the average of the resulting B cross-validated
estimates is the nal B random K-fold cross-validation estimate for the absolute prediction
error of the tted regression model. Generally, the model which yields the smallest cross-
validated absolute prediction error estimate among all candidate models is chosen as the nal
model. On the other hand, a parsimonious model may be chosen if its empirical predicted
error is comparable with that for the best one. We then ret the entire data set with this
selected model for making predictions based on ^():
Note that in the training stage of this cross validation process, a candidate model may be
obtained via a complex variable selection process. For example, a Cox model may be built
with a stepwise regression or lasso procedure. In this case, the nal choice for creating the
score would be retting the entire data set with the selected model building algorithm.
5 Nonparametric Inference About Subject-Specic RMET
Now, let the observed ^() from the nal selected model be denoted by ^opt() and for a future
subject with (Y; Z); let its prediction score be denoted by V = ^opt(Z): That is, for each
future subject, the covariate vector Z is reduced to a one-dimensional V which is a function
of Z: If the selected model is close to the true one, we expect that E(Y jV )  (Z)  V:
In general, however the group mean (v) = E(Y jV = v) by clustering all subjects with
Z, whose ^opt(Z) = v; may be quite dierent from the identity function. Therefore, the
conventional parametric inferences for predicting (v) via the selected model may not be
valid. On the other hand, since we reduce the covariate information to a univariate score V;
10
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one may utilize a nonparametric estimation procedure to draw valid inferences about ():
To make nonparametric inference about (v) simultaneously across a range of the score
v; we use a fresh independent data set or \hold-out" set from the original data set. With
slight abuse of notations, let such a fresh data set be denoted by f(Ui;i; Vi); i = 1;    ; ng:
We propose to use local linear smoothing method to estimate (v) nonparametrically. To
this end, for a score v inside the support of V , let a^ and b^ be the solution of the estimating
equation
Sn(a; b; v) =
nX
i=1
Kh(Vi   v) ~i
G^(Yijv)
0B@ 1
Vi   v
1CAYi   ~ 1fa+ b(Vi   v)g = 0;
where K() is a smooth symmetric kernel function with a nite support, Kh(s) = K(s=h)=h;
h = op(1) is the smoothing bandwidth,
G^(tjv) = exp
(
 
nX
i=1
Z t
0
dNCi (u)Kh(Vi   v)Pn
j=1(Uj  u)Kh(Vj   v)
)
is the local nonparametric estimator for the survival function of C (Dabrowska, 1987, 1989)
and NCi (u) = I(min(Ui; )  u)(1   ~i): Here ~() is a strictly increasing function from
[0;  ] to the entire real line given a priori. The resulting local linear estimator for (v)
is ^(v) = ~ 1(a^). As n ! 1 and nh5 = op(1), (nh)1=2f^(v)   (v)g converges weakly
to a mean zero Gaussian. The details are given in Appendix C. Since the censoring time
C is assumed to be independent of V; generally the nonparametric KM estimator based
on entire sample is used in the inverse probability weighting method for Sn(a; b; v): Here,
we use the local estimator G^(tjv) in the above estimating equation. In the Appendix C,
we show that this estimation procedure results in a more accurate estimator for (v) than
that using G^(): Note that when the empirical distribution of fVi; i = 1;    ;mg is quite
non-uniform, transforming the score via an appropriate function before smoothing could
potentially improve the performance of the kernel estimation (Wand et al., 1991; Park et al.,
11
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1997; Cai et al., 2010).
The aforementioned perturbation-resampling procedure in section 2 can be used to es-
timate the variance of ^(v): To this end, let a^ and b^ be the solution of the perturbed
estimating equation
Sn(a; b; v) =
nX
i=1
Qi
Kh(Vi   v) ~i
G(Yijv)
0B@ 1
Vi   v
1CAYi   ~ 1fa+ b(Vi   v)g = 0;
where
G(tjv) = exp
(
 
nX
i=1
Z t
0
QidN
C
i (u)Kh(Vi   v)Pn
j=1Qj(Uj  u)Kh(Vj   v)
)
:
Then a perturbed estimator for (v) is ^(v) = ~ 1(a^): Conditional on the observed data,
the limiting distribution of (nh)1=2f^(v) ^(v)g approximates the unconditional counterpart
of (nh)1=2f^(v)   (v)g: It follows that one can estimate the variance of ^(v) by ^2(v); the
empirical variance of M realized ^(v)0s. Based on generated ^(v); one may construct
(1  2) condence interval of (v) as

^(v)  c^(v); ^(v) + c^(v)

;
where c is the upper 100 percentage point of the standard normal.
It is important to note that as a process, the standardized ^() does not converge weakly
to a tight process (Bickel & Rosenblatt, 1973). On the other hand, one can use the strong
approximation theory to show that the distribution of the supremum of the standardized
process can still be approximated by that of the supremum of its perturbed counterpart
(Gilbert et al., 2002). It follows that for an interval [v1; v2], a subset of the support of V; the
(1  2) simultaneous condence band of (v); v 2 [v1; v2] can be constructed similarly as
[^(v)  d^(v); ^(v) + d^(v)];
12
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where
pr
(
sup
v2[v1;v2]
j^(v)  ^(v)j
^(v)
< d
 (Ui;i; Vi); i = 1; : : : ; n
)
= 1  2;
where [v1; v2] is an interval within the support of V: Since we require that the bandwidth h
converges to zero at a rate faster than the \optimal" Op(n
 1=5) rate, the bias of ^(v) does
not play any role in the construction of the condence interval or band for (v):
As with any nonparametric function estimation problem, it is crucial to choose an ap-
propriate bandwidth h in order to make proper inference about (v). Here, we propose a
L fold cross-validation procedure to choose an optimal h value which minimizes a weighted
cross-validated absolute prediction error. To this end, we randomly split the data set into L
disjoint subsets of approximately equal sizes, denoted by fIl; l = 1; : : : ; Lg. For any xed h,
we use all observations which are not in Il to obtain an estimator ^( l)(v; h) for predicting
Y , and then estimate the total absolute prediction errors based on observations in Il by
D^l(h) =
X
j2Il
~j
G^(Yj)
Yj   ^( l)(Vj; h) :
Then we may use D^(h) = n 1
PL
l=1 D^l(h) as a nal estimate for the absolute prediction
error. We may choose hopt as the minimizer of D^(h). In practice, to reduce the asymptotic
bias, we propose to use a bandwidth slightly smaller than hopt; which is expected to be in the
order of Op(n
 1=5): For example, h = hoptn 0:05 can be used in local smoothing estimation
(Tian et al., 2005; Cai et al., 2010).
6 Example for Subject-Specic Prediction
In this section, we use a well-known data set from a liver study to illustrate how to build
and select a model, and make inferences simultaneously about the RMETs over a range
of scores created by the nal model. This liver disease study in primary biliary cirrhosis
(PBC) was conducted between 1974 and 1984 to evaluate the drug D-penicillamine, which
13
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was found to be futile with respect to the patient's mortality. The investigators for the study
then used this rich data set to build a prediction model with respect to mortality (Fleming
& Harrington, 1991). There were a total of 418 patients involved in the study including
112 patients who did not participate in the clinical trials, but had baseline and mortality
information. For illustration, any missing baseline value was imputed by the corresponding
sample mean calculated from its observed counterparts in the study. We randomly split the
data set with equal sizes as the training and hold-out sets.
For our analysis, we consider sixteen baseline covariates: gender, histological stage of the
disease (1, 2, 3, and 4), presence of ascites, edema, hepatomegaly or enlarged liver, blood
vessel malformations in the skin, log-transformed age, serum albumin, alkaline phosphotase,
aspartate aminotransferase, serum bilirubin, serum cholesterol, urine copper, platelet count,
standardized blood clotting time and triglycerides. Three models discussed in Section 4
with these covariates included additively were considered in the model selection. They are
the Cox model, the AFT model, and the new RMET model. Moreover, since a Cox model
with ve specic covariates (edema, age, bilirubin, albumin and standardized blood clotting
time) has been established as a prediction model in the literature (Fleming & Harrington,
1991), we also considered the aforementioned three types of models with these ve covariates
additively in our analysis. There are, therefore, six dierent models were considered. Note
that there was no variable selection procedure involved in the model building stage for this
illustration.
Figure 2 shows the KM curve for the patients' survival with the entire data set. The
patients' follow-up times are up to 13 years. Since the tail part of the KM estimate is not
stable. We let  = 10 years for illustration. The overall 10-year survival rate is about 44%.
Table 1 presents the L1 prediction error estimates for the RMET up to 10 years for the
three model building procedures based on 100 random 5-fold cross-validations. With cross-
validation, the L1 prediction error is minimized at 1.94 when the proposed regression model
(1) with the logistic link function () = logf=(   )g based on ve baseline covariates is
14
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utilized.
The nal model is obtained by tting the RMET model with ve covariates:
f(z)g = 6:36  0:14 edema  2:95 log(age) + 0:99 log(bilirubin)
 0:35 log(albumin) + 0:34 log(clotting time):
We then use the score created by this model to make prediction and stratication for subjects
in the hold-out set.
For predicting future restricted event time, we use the procedures proposed in Section 5
to estimate the subject-specic RMET (v) over a range of score v's, and construct its 0.95
pointwise and simultaneous condence intervals over the interval [0:07; 9:52]; where 0.07 and
9.52 are the 2nd and 98th percentiles of observed scores in the holdout set. Here, we let
K() be the Epanechnikov kernel and the bandwidth be 2.1, as selected via cross-validation.
The results are presented in the rst panel of Figure 3. For comparison, we also present
the corresponding results in the second panel of Figure 3 with the survival function of the
censoring time C being estimated based on the entire sample rather than locally as proposed
in Section 5. As expected, the resulting estimator for (v) is less accurate, e.g., the 95%
condence interval for (5) is 24.8% wider when the survival function of C is estimated based
on the entire sample.
As a conventional practice, we may stratify the subjects in the hold-out set into groups
such as low, intermediate and high risk groups by discretizing the continuous score. For
example, we may create four classes based on the quartiles of the scores. Figure 4 presents
the KM curves for these four strata. Visually these curves appear quite dierent. Moreover,
their estimated RMETs and the standard error estimates (in paratheses) are 3.59 (0.46), 6.26
(0.53), 8.50 (0.40), and 9.14 (0.31) in years, respectively. These indicate that the scoring
system does have reasonable discriminating capability with respect to the patients' RMET.
How to construct an \ecient" categorization of the existing scoring system warrants future
15
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research.
7 Remarks
In comparing two groups with censored event time data, the point and interval estimates of
the two RMETs and their counterparts for the group contrast provide much more clinically
relevant information than, for example, the hazard ratio estimate. The results from the HIV
data set from ACTG 320 discussed in the Introduction is a good example, in that the three
drug combination is statistically signicantly better than the conventional therapy, but the
gain from the new treatment with respect to RMET was not as impressive from a clinical
standpoint, likely due to the relatively short follow-up time. Note that for this case, the
median event time cannot be estimated empirically due to heavy censoring. Moreover, we
cannot evaluate models using the individual predicted error, such as the L1 distance function,
with the median event time. It follows that the RMET is probably the most meaningful,
model-free, global measure for the distribution of the event time to evaluate the treatment
ecacy. The choice of  to dene the RMET is crucial, which may be determined at the
study design stage with respect to clinical relevance and feasibility of conducting the study.
Note that one of the attractive features of the model which directly relates the RMET
to its covariates proposed here is that the score created is free of the censoring distribution
even when the model is not correctly specied. On the other hand, those scores built from
the Cox or AFT models depend on the study-specic censoring distribution when the model
is misspecied.
Appendix A: The asymptotic equivalence of ^ and ~
Firstly, for t 2 [0;  ], the KM estimator S^(t) is the solution to the forward integral equation
S(t) = 1 
Z t
0
S(u )d^(u)
16
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and thus
S^(t) = 1 
Z t
0
S^(u )
dN(u)
Y (u)
= 1  1
n
Z t
0
dN(u)
G^(u )
+ op(n
 1=2)
= 1  1
n
nX
i=1
I(Yi  t) ~i
G^(Yi)
+ op(n
 1=2) =
1
n
nX
i=1
I(Yi > t) ~i
G^(Yi)
+ op(n
 1=2)
where N(t) =
Pn
i=1Ni(t); Y (t) =
Pn
i=1 I(Ui  t) and ^() is the Nelsen-Aalen estimator of
the cumulative hazard function of Y: In the above derivation, we have used the fact that
n 1Y (t) = G^(t )S^(t ) + op(n 1):
Therefore
^  ~ = 1
n
nX
i=1
Z 
0
I(Yi > t) ~i
G^(Yi)
dt  ~+ op(n 1=2)
=
1
n
nX
i=1
~i
G^(Yi)
Yi   ~+ op(n 1=2) = op(n 1=2):
Appendix B: The asymptotic properties of ^
It can be shown that S() has an unique solution at  when model (1) is correctly specied.
Let the root of the estimating equation Sn() = 0 be denoted by ^, ^ converges to  in
probability. Furthermore, one can show that
n1=2Sn( ) = n
 1=2
nX
i=1
i + op(1)
where
i = Xi

Yi    1( 0Xi)
	   Z 
0
dMCi (u)
G(u)

Xi

Yi    1( 0Xi)
	 K( ; u) ;
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and
K( ; u) = S(u) 1E

X

Y    1( 0X)	 I(Y  u) :
Coupled with the local linearity of the estimating function, this expansion implies that
n1=2(^  ) converges weakly to a mean zero Gaussian distribution with a variance-covariance
matrix of A 1BA 1; where
A = E

X
2 _ 1( 0X)
	
;
B = E
h
X
2

Y    1( 0X)	2i
+
Z 
0
E

X

Y    1( 0X)	 K( ; u)
2 I(T  u)dC(u)
G(u)
;
_ 1() is the derivative of  1() and a
2 = aa0 for vector a:
Furthermore, one can show that
n1=2(   ^) = A 1n1=2S(^) + o ~P (1) = n 1=2
nX
i=1
(Qi   1)^i + o ~P (1)
where the probability measure ~P is the product measure generated by fQ1; : : : ; Qng and
data,
^i = Xi
n
Yi    1(^0Xi)
o
  n 1=2
Z 
0
dM^Ci (u)
G^(u)
h
Xi
n
Yi    1(^0Xi)
o
  K^(^; u)
i
+ op(1);
M^Ci (u) = I(Ui  u)(1 i) 
R u
0
I(Ui  t)d^C(t) and
K^(; u) =
Pn
i=1Xi fYi    1(0Xi)g I(Ui  u)Pn
i=1 I(Ui  u)
:
Therefore, as n!1 the conditional variance of n1=2(   ^) converges to
A 1(n 1
nX
i=1
^
2i )A
 1;
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which is a consistent estimator of A 1BA 1:
Appendix C: The Asymptotic Properties of ^(v)
Let bh = ~b: As n!1; the estimating equation Sn(a;~b; v) converges to
S(a;~b; v) = fV (v)
0B@
h
(v)  R K(x)~ 1(a+~bx)dxi
  R xK(x)~ 1(a+~bx)dx
1CA ;
where fV () is the density function of V: Since S(a;~b; v) = 0 has an unique root (a;~b) =
(~f(v)g; 0); a^ ! ~f(v)g and hb^ ! 0 in probability as n ! 1: Furthermore, by Taylor
series expansion, we have
(nh)1=2f~ 1(a^)  (v)g
=
n1=2
fV (v)h1=2
nX
i=1
~i
G^(tjv)Kh(Vi   v)

Yi   ~ 1fa0 + b0(Vi   v)g

=
h1=2
n1=2
nX
i=1

Kh(Vi   v)fYi   (Vi)g  
Z 1
0
dMCi (u)
G(u)
Kh(Vi   v) [fYi   (Vi)g  R(u; v)]

+ op(1)
where
R(u; v) =
1(ujv)
ST (ujv) and j(ujv) = E[I(Y  u)fY   (v)g
jjV = v]:
Therefore, by martingale central limit theorem (nh)1=2f~ 1(a^)   (v)g converges weakly to
a mean zero Guassian with variance
2

E[fY   (v)g2jV = v] +
Z 1
0

2(ujv)  1(ujv)
2
ST (ujv)

dC(u)
G(u)

;
where 2 =
R
K(v)2dv: If we use the KM estimator G^(u) to replace G^(ujv) in the estimating
function Sn(a; b; v) and denote the corresponding estimator by ~(v), then one can similarly
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show that the variance of the (nh)1=2f~(v)  (v)g is
2

E[fY   (v)g2jV = v] +
Z 1
0
2(ujv)dC(u)
G(u)

which is greater than that of (nh)1=2f^(v)  (v)g:
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Figure 1: Kaplan-Meier estimates of the survival functions of the two randomized groups
based on the ACTG 320 data
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Figure 2: Kaplan-Meier estimate of the overall patient survival function based on the PBC
data (Solid: point estimate, Dashed: 95% pointwise condence interval
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Figure 3: Estimated subject-specic restricted mean survival time (solid curve) over the
score, and its 95% pointwise (dashed curve) and simultaneous condence intervals (shaded
region). The dotted line is the 45 degree reference line. The survival function of the censoring
time C is estimated locally in the rst panel and based on the entire sample in the second
panel.
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Figure 4: Kaplan-Meier estimates of the survival functions of the four strata divided by
quartiles of the scores based on the PBC data
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Table 1: L1 prediction error estimates for the restricted mean event time up to 10 years of
the three model building procedures based on 100 random 5-fold cross-validations (CV)
L1 prediction error with CV
Cox model AFT model New model
5 covariates 2.34 2.00 1.94
16 covariates 2.34 2.11 2.10
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